Search results
TransCode (RNAZ) Down 50% on Issue of New Common Stock
Zacks via Yahoo Finance· 5 months agoTransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current...
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks via Yahoo Finance· 11 months agoTransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as...
A number of insiders bought TransCode Therapeutics, Inc. (NASDAQ:RNAZ) stock last year, which is...
Simply Wall St. via Yahoo Finance· 2 years agoGenerally, when a single insider buys stock, it is usually not a big deal. However, when several...
Great news for TransCode Therapeutics, Inc. (NASDAQ:RNAZ): Insiders acquired stock in large numbers...
Simply Wall St. via Yahoo Finance· 1 year agoUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders...
Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today
Benzinga via Yahoo Finance· 1 year agoTransCode Therapeutics Inc (NASDAQ: RNAZ) reported preclinical proof-of-mechanism studies with its...
Why TransCode Therapeutics Stock Is Trading Higher Premarket Today
Benzinga via Yahoo Finance· 1 year agoTransCode Therapeutics Inc (NASDAQ: RNAZ) announced acceptance for publication by Frontiers in...
Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'
Benzinga via Yahoo Finance· 2 years agoRNA biotech TransCode Therapeutics Inc (NASDAQ: RNAZ) withdrew its S-1 filing with the SEC that it...
FDA Authorizes TransCode's First-In-Human Clinical Trial With Solid Tumor Patients
Benzinga via Yahoo Finance· 1 year agoTransCode Therapeutics Inc (NASDAQ: RNAZ) has received written authorization from the FDA to proceed...
TransCode Therapeutics Shares Shoot Higher After Encouraging Preclinical Data From Lead Cancer...
Benzinga via Yahoo Finance· 2 years agoTransCode Therapeutics Inc (NASDAQ: RNAZ) reported positive preclinical results with its lead...
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
Zacks via Yahoo Finance· 5 days agoLast week, our time-tested methodologies served investors well in navigating the market. Check out...